Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581098 · ClinicalTrials.gov registry record
miR-200b & miR-21 in Diabetic Wounds
A clinical trial, sponsored by Indiana University.
- Completed
- Registry status
- 98
- Enrollment target
NCT02581098 is a clinical trial that has completed, run by Indiana University. The registered enrollment target is 98 participants.
The verdict
NCT02581098 has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
Study Summary
This study aims to determine if elevated wound-edge endothelial miR-200b is a barrier to wound healing in diabetic patients and also to determine if ex vivo supplementation of miR-21 mimic and recombinant MFG-E8 resolve inflammation in wound macrophages isolated from NPWT sponges from diabetic wounds. This study will enroll 124 (60 in the miR-200b arm and 64 in the miR21 arm) Diabetic Wound patients who have wound tissue oxygenation adequate to support wound healing and will be in the study for 14 weeks that includes 4 study visits.
Interventions
- OTHER No interventions
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2015-08 |
| Est. Completion | 2023-06-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02581098
The ClinicalTrials.gov registry entry for NCT02581098 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No interventions is the first listed.
NCT02581098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02581098 about?
NCT02581098 is a clinical study titled "miR-200b & miR-21 in Diabetic Wounds". This study aims to determine if elevated wound-edge endothelial miR-200b is a barrier to wound healing in diabetic patients and also to determine if ex vivo supplementation of miR-21 mimic and recombinant MFG-E8 resolve inflammation in wound macrophages isolated from NPWT sponges from diabetic wound...
What is the current status of trial NCT02581098?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2015-08. Estimated completion is 2023-06-26.
What interventions are being tested in trial NCT02581098?
The interventions under investigation include: No interventions (OTHER).
Who is sponsoring clinical trial NCT02581098?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.